Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 9:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ranitidine HCL Clear all
No Longer Available No phase listed Expanded access

Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma

NCT02541643
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab
Drug
Lead sponsor
Sundar Jagannath
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2015 · Synced Sep 24, 2026, 9:43 AM EDT
Completed Phase 2 Interventional

A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3

NCT00002106
View directory record Official record
Conditions
HIV Infections
Interventions
Ranitidine hydrochloride
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Sherman Oaks, California • Coral Gables, Florida • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 24, 2026, 9:43 AM EDT
Terminated Phase 3 Interventional

Esophageal Metaplasia Using a Novel Antibody: Reversibility by Proton Pump Inhibitor

NCT00161200
View directory record Official record
Conditions
Esophageal Metaplasia
Interventions
Ranitidine & Pantoprazole
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Sep 24, 2026, 9:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Influence of Medication Taste on Pediatric Prescribers' Prescribing Habits

NCT01734759
View directory record Official record
Conditions
Healthy
Interventions
Taste Test
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 20, 2013 · Synced Sep 24, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT00655850
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Paclitaxel, Gemcitabine, Avastin
Drug · Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 16, 2017 · Synced Sep 24, 2026, 9:43 AM EDT
Withdrawn Not applicable Interventional

In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms?

NCT02700087
View directory record Official record
Conditions
Laryngomalacia, Acid Reflux, Stridor
Interventions
ranitidine or famotidine, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
Up to 4 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 24, 2026, 9:43 AM EDT
Completed Phase 1 Interventional

The Effect of Stomach Acid on Foscarnet

NCT00000964
View directory record Official record
Conditions
HIV Infections
Interventions
Ranitidine hydrochloride, Foscarnet sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 24, 2026, 9:43 AM EDT
Withdrawn Phase 4 Interventional

Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs

NCT00443963
View directory record Official record
Conditions
Dyspepsia
Interventions
Esomeprazole Magnesium
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Sep 24, 2026, 9:43 AM EDT
Withdrawn Phase 4 Interventional

The Study of Eustachian Tube Dysfunction and Laryngopharyngeal Reflux

NCT02123498
View directory record Official record
Conditions
Eustachian Tube Dysfunction, Laryngopharyngeal Reflux
Interventions
Omeprazole, Ranitidine, Pantoprazole, 24-Hour Diagnostic pH-Probe Test, Laryngoscopy
Drug · Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Loma Linda, California • Redlands, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2016 · Synced Sep 24, 2026, 9:43 AM EDT
Terminated Phase 2 Interventional Results available

Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome

NCT00527878
View directory record Official record
Conditions
JOB's Syndrome, Hyper-IgE Recurrent Infection Syndrome, Immune Deficiency
Interventions
Ranitidine, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 24, 2026, 9:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventative Delirium Protocol in Elderly Patients

NCT03541408
View directory record Official record
Conditions
Delirium
Interventions
Control, Preventative Delirium Protocol
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
65 Years to 89 Years
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 24, 2026, 9:43 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation

NCT04294459
View directory record Official record
Conditions
Immune System Disorder
Interventions
Isatuximab SAR650984, Acetaminophen (paracetamol) or equivalent, Ranitidine or equivalent, Diphenhydramine or equivalent, Methylprednisolone or equivalent, Montelukast or equivalent
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
San Francisco, California • Rochester, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 24, 2026, 9:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants

NCT05338502
View directory record Official record
Conditions
Healthy
Interventions
Selpercatinib, Ranitidine, Omeprazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 24, 2026, 9:43 AM EDT
Completed Phase 1 Interventional

Treatment of Orthostatic Hypotension in Autonomic Failure

NCT00223691
View directory record Official record
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 24, 2026, 9:43 AM EDT
Completed No phase listed Observational

Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents

NCT01976078
View directory record Official record
Conditions
Pharmacokinetics, Voriconazole
Interventions
Midazolam/Ranitidine/Esomeprazole
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 18 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 24, 2026, 9:43 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

: Vascular Function in Health and Disease

NCT02966665
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
Interventions
Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4
Other · Drug
Lead sponsor
Russell Richardson
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 24, 2026, 9:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lesinurad Interaction Study With Ranitidine

NCT01908257
View directory record Official record
Conditions
Healthy
Interventions
lesinurad 400 mg, ranitidine 150 mg, lesinurad 400 mg + ranitidine 150 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Sep 24, 2026, 9:43 AM EDT
Completed Phase 1 Interventional Results available

A Study of LY2090314 in Patients With Advanced or Metastatic Cancer

NCT01287520
View directory record Official record
Conditions
Advanced Cancer
Interventions
LY2090314, pemetrexed, Carboplatin, ranitidine
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
25 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Tampa, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 24, 2019 · Synced Sep 24, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer

NCT01248962
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
carboplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Sep 24, 2026, 9:43 AM EDT